JP2006506441A - 免疫応答を増大させるためのｈｍｇｂポリペプチドの使用 - Google Patents

免疫応答を増大させるためのｈｍｇｂポリペプチドの使用 Download PDF

Info

Publication number
JP2006506441A
JP2006506441A JP2004553936A JP2004553936A JP2006506441A JP 2006506441 A JP2006506441 A JP 2006506441A JP 2004553936 A JP2004553936 A JP 2004553936A JP 2004553936 A JP2004553936 A JP 2004553936A JP 2006506441 A JP2006506441 A JP 2006506441A
Authority
JP
Japan
Prior art keywords
box
polypeptide
hmgb
hmgb1
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004553936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506441A5 (https=
Inventor
トレーシー，ケビン，ジェイ．
Original Assignee
ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト filed Critical ノース ショア−ロング アイランド ジュ−イッシュ リサ−チ インスティチュ−ト
Publication of JP2006506441A publication Critical patent/JP2006506441A/ja
Publication of JP2006506441A5 publication Critical patent/JP2006506441A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2004553936A 2002-11-20 2003-11-19 免疫応答を増大させるためのｈｍｇｂポリペプチドの使用 Withdrawn JP2006506441A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42784802P 2002-11-20 2002-11-20
PCT/US2003/036975 WO2004046338A2 (en) 2002-11-20 2003-11-19 Use of hmgb polypeptides for increasing immune responses

Publications (2)

Publication Number Publication Date
JP2006506441A true JP2006506441A (ja) 2006-02-23
JP2006506441A5 JP2006506441A5 (https=) 2006-12-28

Family

ID=32326601

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004553936A Withdrawn JP2006506441A (ja) 2002-11-20 2003-11-19 免疫応答を増大させるためのｈｍｇｂポリペプチドの使用

Country Status (6)

Country Link
US (1) US20060121047A1 (https=)
EP (1) EP1567544A4 (https=)
JP (1) JP2006506441A (https=)
AU (1) AU2003295653B2 (https=)
CA (1) CA2505682A1 (https=)
WO (1) WO2004046338A2 (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013542185A (ja) * 2010-09-09 2013-11-21 ユニバーシティー オブ サザン カリフォルニア バイオフィルムを除去するための組成物および方法
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
JP2020500544A (ja) * 2015-12-11 2020-01-16 ルプレヒト−カールス−ウニベルジテート ハイデルベルク Ｈｍｇｂ１変異体
US10940204B2 (en) 2015-07-31 2021-03-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US11746136B2 (en) 2017-03-15 2023-09-05 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
JP2024518125A (ja) * 2021-05-19 2024-04-24 オックスフォード ユニバーシティ イノベーション リミテッド 組織再生の促進に有用なｈｍｇｂ１関連ポリペプチド、それを含む組成物及びその使用
US12365710B2 (en) 2018-10-05 2025-07-22 Research Institute At Nationwide Children's Hospital HMGB1 protein derivatives for the removal of biofilms

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
WO2006114805A2 (en) * 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
US20090297546A1 (en) * 2006-12-20 2009-12-03 Shino-Test Corporation Avian-derived antibody capable of binding specifically to human hmgb1, immunological determination method for human hmgb1, and immunological determination reagent for human hmgb1
WO2008099913A1 (ja) 2007-02-15 2008-08-21 Kumamoto University ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤
US8227417B2 (en) * 2008-07-25 2012-07-24 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants
US8956618B2 (en) 2010-01-21 2015-02-17 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
MX2012010793A (es) 2010-03-29 2013-05-09 Univ Southern California Composiciones y metodos para la eliminacion de biopeliculas.
NZ604412A (en) 2010-06-09 2015-01-30 Univ Arkansas Vaccine and methods to reduce campylobacter infection
HUE047484T2 (hu) 2013-02-14 2020-04-28 Univ Arkansas Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
CA2906079C (en) 2013-03-15 2022-08-23 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
JP6778681B2 (ja) 2014-12-12 2020-11-04 ザ ファインスタイン インスティテュート フォー メディカル リサーチ Ｈｍｇｂ１媒介性炎症の治療
KR20190015712A (ko) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US20250101204A1 (en) * 2022-02-28 2025-03-27 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for protecting against cell damage and inflammation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
US6323329B1 (en) * 1995-12-21 2001-11-27 Jorn Bullerdiek Nucleic acid sequences of genes encoding high mobility group proteins
US6171779B1 (en) * 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
US6720472B2 (en) * 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6822078B2 (en) * 1996-07-17 2004-11-23 Kaneka Corp. Diagnostic drugs for autoimmune diseases
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) * 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
AU2001245823A1 (en) * 2000-03-17 2001-10-03 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
EP1392844A4 (en) * 2001-05-15 2006-09-06 Long Island Jewish Res Inst USE OF HMG FRAGMENTS AS ANTI-INFLAMMATORY AGENTS
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7220723B2 (en) * 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US20030014155A1 (en) * 2001-07-12 2003-01-16 Applied Material, Inc. High temperature substrate transfer robot

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10595530B2 (en) 2010-09-09 2020-03-24 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
JP2013542185A (ja) * 2010-09-09 2013-11-21 ユニバーシティー オブ サザン カリフォルニア バイオフィルムを除去するための組成物および方法
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US12221472B2 (en) 2013-06-13 2025-02-11 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US11629182B2 (en) 2013-06-13 2023-04-18 Research Institute Of Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US12152068B2 (en) 2013-09-26 2024-11-26 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10570193B2 (en) 2014-01-13 2020-02-25 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11684673B2 (en) 2015-07-31 2023-06-27 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
US10940204B2 (en) 2015-07-31 2021-03-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
US11274132B2 (en) 2015-12-11 2022-03-15 Ruprecht-Karls-Universität Heidelberg Combined preparations of PKM2 modulators and HMGB1
US11072641B2 (en) 2015-12-11 2021-07-27 Ruprecht-Karls-Universitaet Heidelberg HMGB1 tyrosine mutants
JP2020500544A (ja) * 2015-12-11 2020-01-16 ルプレヒト−カールス−ウニベルジテート ハイデルベルク Ｈｍｇｂ１変異体
US11746136B2 (en) 2017-03-15 2023-09-05 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
US12365710B2 (en) 2018-10-05 2025-07-22 Research Institute At Nationwide Children's Hospital HMGB1 protein derivatives for the removal of biofilms
JP2024518125A (ja) * 2021-05-19 2024-04-24 オックスフォード ユニバーシティ イノベーション リミテッド 組織再生の促進に有用なｈｍｇｂ１関連ポリペプチド、それを含む組成物及びその使用

Also Published As

Publication number Publication date
CA2505682A1 (en) 2004-06-03
AU2003295653A1 (en) 2004-06-15
EP1567544A2 (en) 2005-08-31
AU2003295653B2 (en) 2007-08-16
US20060121047A1 (en) 2006-06-08
WO2004046338A3 (en) 2004-09-16
WO2004046338A2 (en) 2004-06-03
EP1567544A4 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
JP2006506441A (ja) 免疫応答を増大させるためのｈｍｇｂポリペプチドの使用
JP7714710B2 (ja) アルブミン結合ドメイン融合タンパク質
EP3227342B2 (en) Proteinaceous heterodimer and use thereof
JP2005512507A6 (ja) 抗炎症剤としてのｈｍｇフラグメントの使用
JP2005512507A (ja) 抗炎症剤としてのｈｍｇフラグメントの使用
JPH09501572A (ja) 精製された霊長類ｃｔｌａ−８抗原および関連する試薬
EP1923463B1 (en) Cancer-rejection antigen peptide derived from glypican-3 (gpc3) for use in hla-a2-positive patient and pharmaceutical comprising the antigen
JP2014111644A (ja) 抗インターフェロンアルファモノクローナル抗体及び使用方法
HUP0202442A2 (hu) Több citokinből és ellenanyagból álló komplexek
JP2006510619A (ja) 抗炎症剤としてのｈｍｇｂ断片の使用
CZ300958B6 (cs) Izolovaný nebo rekombinantní polynukleotid kódující antigenní polypeptid, expresní vektor, hostitelská bunka, protilátka a zpusob prípravy polypeptidu
CN112794911B (zh) 人源化抗叶酸受体1抗体及其应用
US20020054877A1 (en) Mammalian cytokine; related reagents
AU758576C (en) Chemokines with amino-terminal modifications
CN116322785A (zh) 包含il-10的双细胞因子融合蛋白
KR20050067141A (ko) 제어성 ｔ세포의 활성을 제어하는 방법 및 조성물
KR100483480B1 (ko) Ｍｈｃ 클래스 ⅰ과 ｍｈｃ 클래스 ⅱ 분자에 결합하는,ｎｙ-ｅｓｏ-1의 아미노산 서열에 상응하는 분리된펩티드, 및 그것의 사용
KR20010089764A (ko) 인터류킨-17과 관련된 포유류의 사이토카인, 이를코딩하는 폴리뉴클레오티드 및 이의 용도
KR20110030554A (ko) 항아밀로이드 면역원성 조성물, 방법 및 용도
JP2003511019A (ja) Ｉｌ１３変異体
JP2000512855A (ja) 哺乳動物ケモカイン
KR100804885B1 (ko) 경피증의 치료 또는 예방을 위한 ｓａｒｐ-1의 용도
US20120164101A1 (en) Gm-csf and interleukin-21 conjugates and uses thereof in the modulation of immune response and treatment of cancer
SK17612002A3 (sk) Farmaceutická kompozícia na liečenie sklerózy multiplex, ktorá obsahuje interferón
JP7649923B2 (ja) ＧＰＣ３標的化抗体インターフェロンα融合タンパク質及びその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061108

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090915